Rory Riggs

Biography

Mr. Riggs is the CEO and founder of Locus Analytics LLC and Syntax LLC. Mr. Riggs is the former president and board member of Biomatrix, Inc., a NYSE listed biotechnology company that developed and launched Synvisc®. He is chairman and co-founder of Royalty Pharma, the largest investor in revenue producing intellectual property - principally royalty interests in marketed and late stage development biopharmaceutical products. In addition, Mr. Riggs is a co-founder and board member of: Cibus; Fibrogen Inc.; Sugen Inc.; Genenews Ltd; New Ventures LLC and a board member of Intra-cellular Therapeutics, Inc.; New Ventures is an early to growth stage venture capital firm and is one of the principal investors in Cibus. In addition to Cibus, its other portfolio investments include Royalty Pharma; Fibrogen; Intra-cellular Therapies, Koltan, eReceivables and GeneNews. Mr. Riggs received a BA from Middlebury College and an MBA from Columbia University.

Research Interest

medicine